Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; le⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$4.27
Price+23.06%
$0.80
$460.750m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$9.186m
-
1y CAGR-
3y CAGR-
5y CAGR-$257.299m
-1.5%
1y CAGR-14.3%
3y CAGR-14.6%
5y CAGR-$2.51
+1.7%
1y CAGR-3.0%
3y CAGR-2.6%
5y CAGR$354.211m
$420.979m
Assets$66.768m
Liabilities$25.202m
Debt6.0%
-0.1x
Debt to EBITDA-$206.110m
+0.8%
1y CAGR-19.1%
3y CAGR-20.4%
5y CAGR